Consonance and Mohr form specialty pharma effort

Healthcare-focused private equity firm Consonance Capital Partners has teamed up with Jay Mohr to launch a specialty pharmaceutical initiative. Mohr was a co-founder and former managing director of Locust Walk Partners.


NEW YORK, NY and BOSTON, MA – May 22 2018 – Consonance Capital Partners (“Consonance”), a leading healthcare-focused private equity manager, announced today that it has partnered with pharmaceutical industry veteran Jay Mohr to seek out opportunities to acquire, develop and commercialize specialty pharmaceutical products with the intended goal of creating a durable, scalable specialty pharmaceutical platform.

The initial emphasis is anticipated to be on differentiated commercial-stage and cash flow positive targets. Clinical assets in late stage development may at times be considered as part of specific opportunities that also include commercial-stage therapies. Preliminary therapeutic areas of focus include neuropsychiatry, hospital therapeutics, pediatrics and dermatology, though other areas may be opportunistically considered.

Consonance and Mohr together bring a global track record of success in the pharma industry, representing decades of operational, commercial, transaction and investing expertise across multiple therapeutic areas. Jay Mohr has more than 25 years of industry experience encompassing leadership roles in entrepreneurial ventures, as well as P&L, commercial, marketing and business development in large and small pharmaceutical organizations.

Mr. Mohr was also a Co-Founder and former Managing Director of Locust Walk Partners, where he executed numerous value-creating transactions on behalf of life sciences clients. Prior to that, he was co-founder and CEO of Gloucester Pharmaceuticals, which was acquired by Celgene Corporation. Previously, Mr. Mohr also served as President and Chief Business Officer of Variagenics and held various executive positions at Zelos Therapeutics, Serono and Schering-Plough.

“As the pharmaceutical and biotechnology sectors continue to transform, there are more opportunities to build a scaled strategic platform on the back of strong differentiated products that simply no longer fit into a given company’s evolved focus. This initiative enables us to pursue these promising opportunities, and I’m excited to join forces with Consonance given their long history in helping build durable companies of scale” said Jay Mohr.

“During the past three decades, we have partnered with management teams in numerous investments across the healthcare landscape, and our track-record of working on complex transactions, including corporate carve-outs, makes us a very attractive buyer and partner,” said Mitchell Blutt, M.D., Managing Partner of Consonance.

“We look forward to collaborating with Jay to build a platform to better serve the needs of patients and caregivers,” added Ben Edmands, Managing Partner of Consonance.

About Consonance Capital Partners
Consonance Capital Partners invests in private companies in the lower middle market of the U.S. healthcare industry. Consonance Capital Partners’ founders, Mitchell Blutt, MD, Benjamin Edmands, Stephen McKenna, and Nancy-Ann DeParle, partnered together for over a decade while at JPMorgan Partners and its successor and predecessor entities, and have over 80 years of combined experience in private equity investing, primarily within healthcare. Consonance prides itself on building transformative and market leading healthcare companies and has significant experience and extensive relationships in the pharmaceutical sector. Consonance Capital Partners participates in growth equity, leveraged buyout, and recapitalization transactions and is currently investing out of a $500 million fund.